Lin Guey is a seasoned professional in biotherapeutics and research, currently serving as Chief Scientific Officer for Therapeutics Research Ventures (TXRV) and Biotherapeutics at Moderna since May 2022. Prior experience includes the role of Chief Scientific Officer for External Research Ventures (XRV) at Moderna from May 2016 to December 2019, and a Senior Director position focusing on Rare Diseases at Shire from November 2011 to May 2016. Lin also held a Director role in Discovery Biology/Epidemiology at Pfizer from November 2008 to December 2010. Lin's academic background includes a Postdoctoral Research Fellowship in Genetic and Molecular Epidemiology at the CNIO - Spanish National Cancer Research Centre and a PhD in Statistics from Stony Brook University.